ArticleBMC cancer2014
CT based three dimensional dose-volume evaluations for high-dose rate intracavitary brachytherapy for cervical cancer.
Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Point-A vs. volume-based brachytherapy for the treatment of cervix cancer: A meta-analysis.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2022Pooled it
- A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer.BMC cancer · 2016Trial
- Article
- Patient stratification for dose scaling in cervical cancer: a model-based analysis using image-guided adaptive brachytherapy.Journal of radiation research · 2026Article
- A new hyaluronate gel spacer and injection technique for cervical cancer brachytherapy: a technical report.Journal of radiation research · 2025Article
- Dosimetric impact of dose constraint indications using individual patient dose management system for brachytherapy in cervical cancer.Journal of contemporary brachytherapy · 2025Article
- Dosimetric Analysis of Computed Tomography-Based Brachytherapy Planning in Carcinoma Cervix.South Asian journal of cancer · 2025Article
- Effects of target coverage on local recurrence in stereotactic body radiotherapy for early-stage lung squamous cell carcinoma.Japanese journal of radiology · 2025Article
- Development of a deep learning-based model to evaluate changes during radiotherapy using cervical cancer digital pathology.Journal of radiation research · 2025Article
- Optimizing the planning process in computed tomography-based image-guided adaptive brachytherapy for cervical cancer using a spreadsheet-based daily dose management system.Radiological physics and technology · 2025Article
- Reevaluating BED in cervical cancer HDR brachytherapy: source decay and tissue-specific repair significantly impact radiobiological dose.Frontiers in oncology · 2025Article
- Hands-on-training tailored in response to pre-questionnaire-based survey on image-guided brachytherapy effectively reduces anxiety about its implementation.Journal of radiation research · 2024Article
- Effective timing of hyaluronate gel injection in image-guided adaptive brachytherapy for uterine cervical cancer: a proposal of the 'adjusted dose score'.Journal of radiation research · 2024Article
- Transvaginal approach combined intracavitary and interstitial brachytherapy assisted by transrectal ultrasound: results from 30 patients with locally advanced cervical cancer.Japanese journal of radiology · 2024Article
- Clinical advantage and outcomes of computed tomography-based transvaginal hybrid brachytherapy performed only by sedation without general or saddle block anesthesia.Cancer reports (Hoboken, N.J.) · 2022Article
- Tumor size before image-guided brachytherapy is an important factor of local control after radiotherapy for cervical squamous cell carcinoma: analysis in cases using central shielding.Journal of radiation research · 2022Article
- An Asian multi-national, multi-institutional, retrospective study on image-guided brachytherapy in cervical adenocarcinoma and adenosquamous carcinoma.Journal of contemporary brachytherapy · 2022Article
- An Asian multi-national multi-institutional retrospective study comparing intracavitary versus the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical carcinoma.Journal of radiation research · 2022Article
- 3D-Image-Guided Multi-Catheter Interstitial Brachytherapy for Bulky and High-Risk Stage IIB-IVB Cervical Cancer.Cancers · 2022Article
- Non-anesthetist-administered moderate sedation with midazolam and fentanyl for outpatient MRI-aided hybrid intracavitary and interstitial brachytherapy in cervix cancer: a single-institution experience.Journal of contemporary brachytherapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, high risk clinical target volumes (HR-CTVs) according to GEC-ESTRO guideline were contoured retrospectively based on CT images taken at the time of high-dose rate intracavitary brachytherapy (HDR-ICBT) and correlation between clinical outcome and dose of HR-CTV were analyzed.
methodsOur study population consists of 51 patients with cervical cancer (Stages IB-IVA) treated with 50 Gy external beam radiotherapy (EBRT) using central shield combined with 2-5 times of 6 Gy HDR-ICBT with or without weekly cisplatin. Dose calculation was based on Manchester system and prescribed dose of 6 Gy were delivered for point A. CT images taken at the time of each HDR-ICBT were reviewed and HR-CTVs were contoured. Doses were converted to the equivalent dose in 2 Gy (EQD2) by applying the linear quadratic model (α/β = 10 Gy).
resultsThree-year overall survival, Progression-free survival, and local control rate was 82.4%, 85.3% and 91.7%, respectively. Median cumulative dose of HR-CTV D90 was 65.0 Gy (52.7-101.7 Gy). Median length from tandem to the most lateral edge of HR-CTV at the first ICBT was 29.2 mm (range, 18.0-51.9 mm). On univariate analysis, both LCR and PFS was significantly favorable in those patients D90 for HR-CTV was 60 Gy or greater (p = 0.001 and 0.03, respectively). PFS was significantly favorable in those patients maximum length from tandem to edge of HR-CTV at first ICBT was shorter than 3.5 cm (p = 0.042).
conclusionVolume-dose showed a relationship to the clinical outcome in CT based brachytherapy for cervical carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.